Press releases
- Newron Reports Compelling Topline Results From All Patients in Study 014, Its Phase II Clinical Trial Evaluating Evenamide as Add-on Therapy for Treatment-resistant Schizophrenia
- Newron to present at the 31st European Congress of Psychiatry
- Newron Announces 2022 Financial Results and Provides Outlook For 2023
- Newron Reports Striking One-Year Interim Efficacy Results From Its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Patients With Treatment-Resistant Schizophrenia
- Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
More ▼
Key statistics
On Friday, Newron Pharmaceuticals SpA (NP5:BER) closed at 6.08, -26.03% below its 52-week high of 8.22, set on Feb 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.08 |
---|---|
High | 6.14 |
Low | 5.98 |
Bid | -- |
Offer | -- |
Previous close | 6.10 |
Average volume | 2.53k |
---|---|
Shares outstanding | 17.85m |
Free float | 16.96m |
P/E (TTM) | -- |
Market cap | 106.70m CHF |
EPS (TTM) | -0.9764 CHF |
Data delayed at least 15 minutes, as of Mar 24 2023 20:50 BST.
More ▼